Logo American Journal of Case Reports

Call: 1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo American Journal of Case Reports Logo American Journal of Case Reports Logo American Journal of Case Reports

04 April 2021: Articles  Greece

Giant Adrenocortical Carcinoma: A Case Report and Review of the Relevant Literature

Unusual or unexpected effect of treatment, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)

Ioannis Mantzoros1ADE, Stefanos Bitsianis1ADEF, Lydia Loutzidou1BCDEF, Georgios Ntampakis1BDEF, Christos Chatzakis1CDE, Panagiotis Christidis1BEF*, Anna Gkiouliava2AE, Eleni Koraki2AE, Stamatios Aggelopoulos1EFG

DOI: 10.12659/AJCR.928875

Am J Case Rep 2021; 22:e928875

0 Comments

Abstract

BACKGROUND: Adrenocortical carcinomas are rare and aggressive tumors often diagnosed as incidentalomas. The malignancy can present with abnormal hormone secretion or the tumor may be non-functioning and present as a palpable mass causing discomfort. Here, we present a case of an adrenal cortical carcinoma originally identified as an incidentaloma.

CASE REPORT: A 63-year-old woman presented with abdominal pain and discomfort. A large abdominal mass, occupying the left upper and lower quadrant, was palpated. Imaging revealed a mass occupying the left abdomen between the stomach and the spleen, applying pressure on the pylorus, duodenum, splenic vessels, and pancreas. The mass size was 21.2×13×14.6 cm. Hormonal investigations were normal. Surgical exploration was performed, and the tumor was excised. Pathological analysis revealed an adrenocortical carcinoma and the patient underwent adjuvant chemotherapy. Twelve months later, the carcinoma recurred. The patient underwent a second operation in which the recurrent mass was excised along with the tail of the pancreas and a small part of the left lobe of the liver. The postoperative period was uneventful, and the patient was discharged home on the 7th postoperative day. No further adjuvant therapy was applied. The patient remains disease-free 18 months after the reoperation.

CONCLUSIONS: Giant adrenocortical carcinomas, although rare, pose a challenge to the surgical team both diagnostically and therapeutically. Surgical excision with the appropriate oncologic support can guarantee excellent outcomes.

Keywords: Adrenal Gland Neoplasms, adrenocortical carcinoma, case reports, Incidental Findings, mitotane, Adrenal Cortex Neoplasms, Combined Modality Therapy, Liver, Middle Aged, Neoplasm Recurrence, Local

Background

Adrenocortical carcinomas (ACC) are rare and frequently aggressive tumors. Their worldwide incidence is estimated at 2 per million cases annually in the USA, affecting women more frequently than men [1]. The 5-year survival rate varies from 15% to 84% and is directly correlated with the stage of the cancer at presentation [2]. ACCs can be divided in 2 groups: functioning (hormone-producing) and non-functioning tumors [3].

The clinical presentation depends on the size, location, and hormonal production status. A large tumor can be the cause of abdominal pain and discomfort to the patient due to a mass effect. The patient might also present with generalized symptoms such as weight loss, malaise, and dyspnea [4].

The cornerstone therapy has always been complete surgical removal of the tumor and adjacent organs. Adjuvant chemo-therapy with mitotane and cytotoxic factors can be used for functional adrenal carcinomas according to the stage of the disease and the status of the patient [5].

Here, we present the case of a patient with a large abdominal mass that turned out to be ACC and the patient underwent a radical surgical resection.

Case Report

A 63-year-old woman was referred from the gastroenterology clinic of our hospital to our unit with a giant solid mass in the upper abdomen of unknown origin. Her initial symptoms were abdominal pain and discomfort. Her past medical history included type II diabetes mellitus treated with metformin and a history of hysterectomy for uterine fibroids. On examination, a large abdominal mass was palpated occupying mostly the left upper and lower abdominal quadrant. Upper gastrointestinal endoscopy was normal. After investigation with CT and MRI abdominal scans (Figures 1, 2, respectively), a mass was found occupying the left abdomen, located between the stomach and the spleen. The mass was shown to originate from the left pararenal space extending to the greater curvature of the stomach, applying pressure to the pylorus, duodenum and splenic vessels, as well as being in direct contact with the pancreas (Figure 1). Due to the size (21.2×13×14.6 cm) and location of the mass, an adrenocortical carcinoma was suspected. After biochemical studies, no hormonal abnormalities were discovered (serum cortisol level: 188 ng/ml, normal reference range: 50–230 ng/mL), dehydroepiandrosterone level: 67 μg/dl (normal reference range: 45–270 μg/mL), plasma fractioned metanephrines 31 pg/mL (normal reference range: 12–60 pg/mL), plasma fractioned normetanephrines 75 pg/mL (normal reference range: 18–111 pg/mL), and aldosterone-torenin ratio of <20 (normal reference range: 20–40).

The patient underwent an extended open surgical excision of the mass along with the stomach that was attached to it (Figure 3). An esophago-jejunal anastomosis and a side-to-side jejuno-jejunal anastomosis were performed. Resection margins were clear of residual mass, confirmed by frozen section study. Due to the duration of the operation (3.5 hours) and the co-morbidities of the patient (diabetes mellitus, obesity) she was transferred to the Intensive Care Unit (ICU) for postoperative resuscitation and remained there for the first 24 hours. In the immediate postoperative period, she developed a lower respiratory tract infection that was treated successfully with intravenous antibiotics. Otherwise, her postoperative period was uneventful and she was discharged home on the 22nd day.

The histology exam revealed that the mass was an adrenal cortical neoplasm (WHO 2004 Classification-tumors of endocrine organs) with the following immunochemistry profile: vimentin (+), CD56 (+), synaptophysin (+), melan-A (+/–), calretinin (+/–), CD138 (+). The modified Weiss score system incorporates the following criteria: 1) mitotic rate >5 per 50 high-power fields, 2) cytoplasm (clear cells comprising 25% or less of the tumor), 3) abnormal mitoses, 4) necrosis, and 5) capsular invasion. According to the system, each of these criteria is differently weighted and a score of 3 or more suggests malignancy [6]. In our patient, the modified Weiss score system of 6, size of 20 cm in diameter, and the ki-67 proliferation index of 5–7% were all suggestive of carcinoma. The patient underwent adjuvant chemotherapy postoperatively with mitotane treatment.

Despite adjuvant therapy, she presented with a cystic lesion 1 year after the operation. A CT-guided core biopsy was performed, which revealed recurrent adrenocortical carcinoma (Figure 4). The recurrence was located posterior lateral to the esophagojejunal anastomosis (Figure 5A). She underwent a second operation in which the recurrent mass was excised along with the tail of the pancreas and a small part of the left lobe of the liver (Figure 5B). The postoperative period was uneventful, and the patient discharged home on the 7th postoperative day. No further adjuvant therapy was applied. The patient undergoes follow-up with CT scan every 6 months, which revealed no recurrence 1.5 year after the reoperation, and no metastasis was observed.

Discussion

Adrenal cortical carcinoma (ACC) is an uncommon malignant endocrine neoplasm. ACC accounts for 0.02% of all cancers reported annually in the United States. It has an estimated incidence of 0.02 to 0.2 cases per million population per year [7]. The clinical presentation of adrenal cortical tumors depends on their size and hormonal status. Many non-functioning adrenal tumors are incidental findings and not always related to the patient’s clinical presentation, and are therefore called incidentalomas [8].

Less than 2% of incidentalomas under 4 cm in size are primary adrenal carcinomas, while the risk for adrenal carcinoma increases to 25% in adrenal masses greater than 6 cm. The sensitivity and specificity for cutoffs of 4 cm are 98% and 59%, respectively [9,10]. Our patient presented with an abdominal mass of 21.2×13×14.6 cm, which rarely has an adrenal origin.

After thorough review of the literature, cases of adrenal carcinomas larger than 12 cm were documented (Table 1) [3–5,7,11–20]. The mean size of these tumors was 18 cm. The largest tumor, reported by Bacalbasa et al, was 35 cm [21]. The size of the tumor we resected was at the 74th percentile of the normal distribution curve. The tumor appears to be larger than the mean tumor size reported in the literature (Figure 6). The clinical manifestation of ACCs depends on their hormone-producing status. Non-functioning tumors can present with unspecific symptoms like abdominal pain, malaise, hematuria, and weight loss or no symptoms at all (incidental findings). Functioning tumors have a varied presentation, including Cushing’s syndrome, virilization, and feminization [8]. Our patient had non-specific symptoms, none of which were associated with hormone production (abdominal pain, discomfort, palpable abdominal mass). Blood hormonal levels where within normal levels. The imaging studies that are most commonly and effectively used for the differential diagnosis between the types of adrenal masses are non-contrast CT, MRI, and adrenal scintigraphy [5].

The laboratory tests used for the differential diagnosis for adrenal masses depends on the clinical signs of hormonal production. In cases of obvious endocrine symptomatology there are a number of measurements that indicate the functionality of the mass. Dexamethasone suppression test and 24-hour urine cortisol sample are used in the presence of Cushing’s syndrome, while plasma estradiol or estrone is measured when feminization is present [5,8]. When an adrenal lesion is incidentally found, appropriate laboratory tests to be performed are electrolyte levels measurement in the presence of hypertension to rule out hyperaldosteronism, urinary metanephrines and catecholamines levels to exclude pheochromocytoma, and estrogen or androgen levels where relevant symptoms exist [8]. Our patient underwent an abdominal CT and MRI scan, in which the mass was found, and a full blood biochemical work-up including cortisol, aldosterone, renin, metanephrines, normetaphrines, and dehydroepiandrosterone level measurement.

Radical surgical resection is suggested for all patients presenting with adrenal tumor (stage I, II, or III disease), while achieving an R0 excision remains the most important prognostic factor for survival. Laparoscopic adrenalectomy is an option for experienced surgeons and masses <6 cm, whereas open adrenalectomy remains the suggested option for larger masses, signs of local invasion, or if carcinoma/malignancy is suspected [22].

We performed an extended surgical excision of the tumor along with the stomach that was attached to it and completed the operation with the appropriate anastomosis (esophago-jejunal anastomosis and a side-to-side jejuno-jejunal anastomosis). Radical resection is also the criterion standard strategy for recurrence. Similarly, the attached organs such as the left liver lobe and the tail of the pancreas were excised along with the recurrent mass. Our patient needed a second operation 1 year later due to recurrence, but she remains cancer free to date.

Mitotane, as a single agent or in combination with other cytotoxic drugs, is the current standard treatment for advanced ACCs [23]. Treatment regimens in ACC are mitotane mono-therapy, EDP-M (etoposide, doxorubicin, cisplatin plus mitotane), or streptozotocin plus mitotane. However, time to progression was observed to be significantly better in patients treated with mitotane [20]. In our case, despite open radical excision and adjuvant chemotherapy with mitotane, adreno-cortical carcinoma reoccurred after 1 year.

Recently, gene expression profiling has improved our understanding of the oncogenesis of ACC and helped identify potential new targets for treatment [20]. New avenues for ACC therapy have been opened by studies investigating the biological and molecular bases of this disease [23]. Several pathways have been identified in the tumorigenesis of ACC. IGF-2, mTOR, EGFR, and VEGF are overexpressed in ACC [23]. In vitro and in vivo studies have been performed to identify potential targeted therapies for ACC [20]. Those include IGF-1 receptor antagonists, β-catenin antagonists, SF-1 (steroidogenic factor 1) inverse agonists, and mTOR antagonists. PPARγ and estrogen receptors have also been identified as potential markers for ACC tumor-genesis [23].

Conclusions

Non-functioning adrenal incidentalomas are rare and present with vague symptoms such as dull abdominal pain, nausea, and discomfort. Their size is a strong indicator of their malignant potential. Masses larger than 6 cm have increased risk being carcinomas. The criterion standard treatment for adrenocortical carcinomas is open radical excision with adjuvant chemotherapy, although the recurrence rate and disease-fee survival remain unsatisfactory.

References:

1.. Bilimoria KY, Shen WT, Elaraj D, Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors: Cancer, 2008; 113(11); 3130-36

2.. Kim Y, Margonis GA, Prescott JD, Nomograms to predict recurrence-free and overall survival after curative resection of adrenocortical carcinoma: JAMA Surg, 2016; 151(4); 365-73

3.. Hatano M, Takenaka Y, Inoue I, Feminizing adrenocortical carcinoma with distinct histopathological findings: Intern Med, 2016; 55(22); 3301-7

4.. Benassai G, Desiato V, Benassai G, Adrenocortical carcinoma: What the surgeon needs to know. Case report and literature review: International Journal of Surgery, 2014; 12; S22-28, Elsevier Ltd

5.. Uruc F, Urkmez A, Yuksel OH, Androgen secreting giant adrenocortical carcinoma with no metastases: A case report and review of the literature: Can Urol Assoc J, 2015; 9(9–10); E644-47

6.. Aubert S, Wacrenier A, Leroy X, Weiss system revisited: A clinicopathologic and immunohistochemical study of 49 adrenocortical tumors: Am J Surg Pathol, 2002; 26(12); 1612-19

7.. Phan AT, Adrenal cortical carcinoma-review of current knowledge and treatment practices: Hematology/Oncology Clinics ofrth America. Hematol Oncol Clinrth Am, 2007; 21; 489-507

8.. Alastrué Vidal A, Navinés López J, Julián Ibáñez JF, Adrenohepatic fusion: Adhesion or invasion in primary virilizant giant adrenal carcinoma? Implications for surgical resection. Two case report and review of the literature: Int J Surg Case Rep, 2016; 18; 24-29

9.. Ye Y, Yuan X, Chen M, Management of adrenal incidentaloma: the role of adrenalectomy may be underestimated: BMC Surg, 2016; 16(1); 41

10.. Grumbach MM, Biller BMK, Braunstein GD, Management of the clinically inapparent adrenal mass (“incidentaloma”): Ann Intern Med, 2003; 138(5); 424-29

11.. Permana H, Darmawan G, Ritonga E, An interesting case of hepatic adrenocortical carcinoma: Acta Med Indones, 2018; 50(3); 257-59

12.. Meshikhes AWN, Abdel Gawad WM, Al-Saeed JY, Young male with left adrenal mass: BMJ Case Rep, 2016; 2016; bcr2016215669

13.. Chentli F, Terki N, Azzoug S, Ectopic adrenocortical carcinoma located in the ovary: Eur J Endocrinol, 2016; 175(4); K17-23

14.. Habibi M, Karakoyun R, Demirci E, Alikanoglu AS, Chylous ascites after re-section of giant adrenocortical carcinoma: Gland Surg, 2016; 5(6); 639-43

15.. Sung TY, Choi YM, Kim WG, Myxoid and sarcomatoid variants of adrenocortical carcinoma: Analysis of rare variants in single tertiary care center: J Korean Med Sci, 2017; 32(5); 764-71

16.. Ghorayeb N El, Grunenwald S, Nolet S, First case report of an adrenocortical carcinoma caused by a BRCA2 mutation: Medicine (Baltimore), 2016; 95(36); e4756

17.. Saeger W, Mohren W, Behrend M, Sarcomatoid adrenal carcinoma: Case report with contribution to pathogenesis: Endocr Pathol, 2017; 28(2); 139-45

18.. Esquivel DV, Batiz F, Vega AF, Carrillo Gonzalez PA, Adrenocortical carcinoma, an unusual cause of secondary hypertension: BMJ Case Rep, 2016; 2016; bcr2016217918

19.. Estévez Fernández S, Artime Rial M, Domínguez Comesaña E, Sánchez Santos R, Giant adrenal cortical carcinoma: Cir Esp, 2017; 95(9); 542

20.. Maluf DF, de Oliveira BH, Lalli E, Therapy of adrenocortical cancer: Present and future: Am J Cancer Res, 2011; 1(2); 222-32

21.. Bacalbasa N, Terzea D, Jianu V, Multiple visceral resection for giant non-secretory adrenocortical carcinoma in an elderly patient: A case report: Anticancer Res, 2015; 35(4); 2169-74

22.. Fassnacht M, Arlt W, Bancos I, Dralle H, Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors: Eur J Endocrinol, 2016; 175(2); G1-34

23.. Aufforth RD, Nilubol N, Emerging therapy for adrenocortical carcinoma: Int J Endocr Oncol, 2014; 1(2); 173-82

SARS-CoV-2/COVID-19

04 July 2022 : Case report  Italy

Interleukin-6 Is a Promising Marker of COVID-19 in Children: A Case Series of 2 Brothers with Severe COVID-...

Am J Case Rep In Press; DOI: 10.12659/AJCR.934468  

29 June 2022 : Case report  USA

A Clinical Case of COVID-19 Vaccine-Associated Guillain-Barré Syndrome

Am J Case Rep In Press; DOI: 10.12659/AJCR.936896  

16 June 2022 : Case report  Ecuador

Multidrug-Resistant Klebsiella pneumoniae in a Patient with SARS-Cov-2 Pneumonia in an Intensive Care Unit ...

Am J Case Rep In Press; DOI: 10.12659/AJCR.936498  

13 June 2022 : Case report  Japan

Stenotrophomonas maltophilia Infection Associated with COVID-19: A Case Series and Literature Review

Am J Case Rep In Press; DOI: 10.12659/AJCR.936889  

In Press

05 Jul 2022 : Case report  Saudi Arabia

Osteolytic Lesion of the Maxilla in an Undiagnosed Multiple Myeloma Patient Identified Incidentally by Cone...

Am J Case Rep In Press; DOI: 10.12659/AJCR.936585  

05 Jul 2022 : Case report  USA

Histiocytic Disorder Mimicking a Brain Tumor: A Report of 2 Rare Cases

Am J Case Rep In Press; DOI: 10.12659/AJCR.935885  

05 Jul 2022 : Case report  Greece

Solitary Soft-Tissue Metastasis of a Pancreatic Adenocarcinoma 2 Years After Curative Resection: Report of ...

Am J Case Rep In Press; DOI: 10.12659/AJCR.934951  

05 Jul 2022 : Case report  Switzerland

Degenerated Serous Cystic Tumor of the Pancreas: Case Report and Literature Review of an Aggressive Present...

Am J Case Rep In Press; DOI: 10.12659/AJCR.936165  

Most Viewed Current Articles

23 Feb 2022 : Case report  USA

Penile Necrosis Associated with Local Intravenous Injection of Cocaine

DOI :10.12659/AJCR.935250

Am J Case Rep 2022; 23:e935250

17 Feb 2022 : Case report  Oman

Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of P...

DOI :10.12659/AJCR.934399

Am J Case Rep 2022; 23:e934399

06 Dec 2021 : Case report  Brazil

Lipedema Can Be Treated Non-Surgically: A Report of 5 Cases

DOI :10.12659/AJCR.934406

Am J Case Rep 2021; 22:e934406

09 Feb 2022 : Case report  Saudi Arabia

Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COV...

DOI :10.12659/AJCR.934744

Am J Case Rep 2022; 23:e934744

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

American Journal of Case Reports eISSN: 1941-5923
American Journal of Case Reports eISSN: 1941-5923